Labsystems Diagnostics Oy
Labsystems Diagnostics Oy is a Finnish in-vitro diagnostics company and subsidiary of Trivitron Healthcare that develops newborn screening instruments and reagent kits (tandem MS, immunoassays, PCR) sold to clinical laboratories and hospitals across 70+ countries, holding the #2 global position in NBS technology.
- Company typePrivate
- Founded1984
- HeadquartersVantaa, Finland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Labsystems Diagnostics Oy does
Labsystems Diagnostics Oy is a Finnish in-vitro diagnostics company that develops, manufactures, and markets diagnostic products centered on newborn screening (NBS), with additional offerings in enzyme immunoassays (EIA, FEIA), LC-MS assays, molecular diagnostics (MDx), and point-of-care (POC) tests. Founded in the early 1980s and headquartered in the Helsinki metropolitan area (Vantaa), the company was acquired by Indian medical technology conglomerate Trivitron Healthcare in 2012 and operates as a key diagnostic division of the group, including a manufacturing IVD Factory in Mumbai inaugurated in 2016. Its technology stack combines high-throughput instrumentation — the NS2400 platform capable of processing over 2,000 baby samples per run and the NS496 Plus DBS Puncher — with proprietary reagent kits such as the patented NeoMass AAAC kit (world's first to detect up to 50 inborn metabolic disorders via tandem mass spectrometry), the NeoMass AAAC Plus kit, CAH MASS second tier kit, SCID-SMA multiplex PCR kit, Neonatal T4 FEIA kit, and Neonatal GALT kit.
The company reports the #2 global position in newborn screening technology and serves clinical laboratories, hospitals, and physicians' offices across more than 70 countries. Its go-to-market combines a layered distributor network — including Oxford Biosystems (UK/Ireland), Fur Med (Northern Iraq), Baebies (US), and additional regional partners — with direct enterprise field sales targeting high-volume screening programs. Revenue derives primarily from one-time instrument sales and recurring reagent kit sales (NeoMass panels, immunoassays, QC sera). Strategic partnerships with Shimadzu (mass spectrometry instrumentation) and Baebies (SEEKER lysosomal storage disease platform) round out an integrated NBS ecosystem.
Labsystems Diagnostics operates as a private subsidiary within the Trivitron Healthcare conglomerate and is led by CEO Dr. Geraldine Carrard, with Sameer Saral as COO and Nikhil Bedekar as President. Trivitron's broader R&D pipeline of 35+ products under development provides product cadence and cross-pollination across lab medicine, imaging, cardiology, OR/ICU, and renal care, although revenue, headcount trends, and growth KPIs for the Labsystems division itself are not publicly disclosed.
Labsystems Diagnostics Oy firmographics
Firmographics- Name
- Labsystems Diagnostics Oy
- Legal name
- Labsystems Diagnostics Oy
- Website
- https://labsystemsdx.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Labsystems Diagnostics Oy is a Finnish in-vitro diagnostics company and subsidiary of Trivitron Healthcare that develops newborn screening instruments and reagent kits (tandem MS, immunoassays, PCR) sold to clinical laboratories and hospitals across 70+ countries, holding the #2 global position in NBS technology.
- Ownership category
- akta.pro rank
Labsystems Diagnostics Oy industry classification
Industry- Product category
- In-Vitro Diagnostics / Newborn Screening
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Newborn Screening & Genetic Public Health Laboratories (HLAJAIAJ)
Keywords
Where Labsystems Diagnostics Oy is headquartered
LocationHeadquarters
- HQ city
- Vantaa
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Labsystems Diagnostics Oy business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Products Sales: Sale of diagnostic products including newborn screening kits, instruments, reagents, and point-of-care tests to clinical laboratories, hospitals, and healthcare providers globally
- Reagent Kits: Sale of specialized reagent kits including enzyme immunoassays, LC-MS reagents, and specialized screening panels
- Instrumentation: Sale and distribution of diagnostic instruments including automated systems, modular NBS instrumentation, and laboratory equipment
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Labsystems Diagnostics Oy product offering
Product offeringCore offering
Labsystems Diagnostics Oy develops, manufactures, and markets in-vitro diagnostic products centered on newborn screening, with a complementary portfolio in infectious disease, gastroenterology, clinical biochemistry, point-of-care testing, and life sciences. The company sells reagent kits (tandem MS-based NeoMass AAAC for 50+ inborn metabolic disorders, CAH second tier, SCID-SMA multiplex PCR, FEIA kits), automated instruments (NS2400 high-throughput robotic platform, NS496 Plus DBS Puncher), and consumables to clinical laboratories, hospitals, and screening programs in 70+ countries.
Product overview
Labsystems Diagnostics Oy operates as a comprehensive diagnostic solutions provider, developing, manufacturing and marketing high quality diagnostic products for clinical laboratories and physicians. The portfolio centers on newborn screening (NBS) technology where the company holds the #2 global market position, encompassing instruments (NS2400 high-throughput platform, modular/automated NBS instrumentation, NS496 Plus DBS puncher), assay kits (NeoMass AAAC/AAAC Plus tandem MS reagents, CAH MASS second tier kit, SCID-SMA Multiplex PCR kit, Neonatal T4 FEIA, Neonatal GALT), and specialty technologies (LC-MS, Point of Care, EIA, Fluoro Enzymatic Assays). Extended offerings include Infectious Disease tests, Gastroenterology products, Clinical Diagnostics (cardiac markers), and Life Sciences (Custom Oligonucleotides, Protein Enzymes). Products are distributed globally to more than 70 countries. Labsystems is a Trivitron Healthcare Group enterprise.
Differentiator
Problem solved
Functional benefit
Products and services
- NeoMass AAAC Kit World's first-of-its-kind tandem mass spectrometry reagent kit for expanded newborn screening that detects up to 50 inborn metabolic disorders, including amino acids, free carnitine, acylcarnitines, succinylacetone, and argininosuccinic acid, using a non-derivatized method. CE Approved; for clinical laboratories performing newborn screening.
- NeoMass AAAC Plus Kit Expanded tandem MS newborn screening panel for quantitative determination of 15 amino acids, free carnitines, 12 acylcarnitines, argininosuccinic acid (ASA) and succinylacetone (SUAC) using a single extraction and single injection on tandem mass spectrometry. For clinical newborn screening laboratories.
- CAH MASS Second Tier Test Kit First LC-MS/MS quantitative kit measuring 17-Hydroxyprogesterone, Androstenedione, Cortisol, 11-Deoxycortisol and 21-Deoxycortisol in dried blood spot samples; used as second-tier and confirmatory diagnostic for congenital adrenal hyperplasia (CAH). For clinical newborn screening laboratories.
- SCID-SMA Multiplex PCR Kit Molecular diagnostic PCR kit for rapid and simultaneous detection of Severe Combined Immunodeficiency (SCID) syndrome and Spinal Muscular Atrophy (SMA) in newborns using DNA from whole blood or dried blood spots. For newborn screening laboratories.
- NS496 Plus DBS Puncher Automated laboratory sample preparation instrument with air humidification system and clean punch mechanism that punches dried blood spot samples into 96-well microtitre plates for subsequent NBS analysis. For clinical newborn screening laboratories.
- Neonatal T4 FEIA Kit Fluorescence-based newborn screening kit for quantitative determination of total Thyroxine (T4) from dried blood spots, used to screen newborns for congenital hypothyroidism (CH). For clinical newborn screening laboratories.
- Neonatal GALT Kit Fluorescence-based newborn screening kit for quantitative determination of galactose-1-phosphate uridyl transferase (GALT) from dried blood spots, used to screen newborns for classic galactosemia. For clinical newborn screening laboratories.
- NS2400 Platform Fully integrated robotic high-throughput platform for newborn screening that performs enzymatic assays and immunoassays and can test over 2000 baby samples in a single run. CE marked; for clinical newborn screening laboratories.
- NBS Instruments Modular and fully automated newborn screening instrumentation portfolio, including manual and automated equipment, designed for precise, high-performance newborn screening programs. For clinical newborn screening laboratories.
- Point of Care Tests Rapid diagnostic tests performed at bedside or point-of-care, including cardiac marker POC tests and thyroid tests for newborns within the first five days of life. For physicians' offices, clinics, and home use.
- Infectious Disease Diagnostic Tests Diagnostic tests for infectious agents demonstrating presence or absence of infections using specimens such as urine, blood, sputum, and cerebro-spinal fluid. For clinical laboratories and healthcare providers.
- Gastroenterology Diagnostic Tests Diagnostic tests for conditions affecting the gastrointestinal (GI) system, supporting gastroenterologists in identifying the source of a condition and planning treatment. For gastroenterology practices and clinical laboratories.
- Clinical Diagnostics / Cardiac Marker POC Tests Clinical biochemistry products, including cardiac marker point-of-care tests for various diagnostic applications. For clinical laboratories and point-of-care settings.
- Life Sciences Products (Custom Oligonucleotides and Protein Enzymes) Custom oligonucleotides and protein enzymes for life science applications, healthcare research, and biotechnology. For life sciences research organizations and biotechnology companies.
- Quality Control Sera Quality control sera for laboratory diagnostics, used to ensure the accuracy and reliability of test results. For clinical laboratories.
Companies that use Labsystems Diagnostics Oy
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Labsystems Diagnostics Oy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Labsystems Diagnostics Oy partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, minor and flagship.
- BaebiescoreBilateral distribution agreement signed in September 2017. Baebies distributes Labsystems' newborn screening products (including NeoMass AAAC and NS 2400) in the U.S. market after regulatory clearance. Labsystems distributes Baebies' SEEKER platform internationally. The partnership provides comprehensive newborn screening solutions to customers globally, combining Labsystems' enzymatic and immunoassay products with Baebies' lysosomal storage disease testing platform.
- Fur MedminorDealer representation at Fourth International Conference of Iraqi Kurdistan Pediatric Society in May 2017. Fur Med participated on behalf of Labsystems Diagnostics to display NBS products and explore business opportunities in the Northern Iraq region.
- Shimadzu Corporation JapanflagshipJoint Association announced in September 2016 for clinical diagnostics in newborn screening. The partnership combines Labsystems' reagent technology leadership with Shimadzu's world-class mass spectrometry instrumentation. Companies cooperate to enable global customers to detect more disorders in newborns more rapidly and with greater accuracy. Labsystems' NeoMass AAAC assay is fully validated on Shimadzu platforms, detecting the broadest range of non-derivatized analytes available for urea cycle metabolic disorders.
- Oxford BiosystemscoreDealership relationship agreement signed September 2016 for UK and Ireland markets. Oxford Biosystems sells and supports Labsystems Diagnostics products including infectious disease, point of care, PCR, gastro, and newborn screening products. The partnership leverages Oxford Biosystems' local presence and technical support capabilities to enhance Labsystems' market coverage in the UK and Ireland.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Labsystems Diagnostics Oy competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Labsystems Diagnostics Oy social profiles
Digital presenceLabsystems Diagnostics Oy compliance and trust
Trust signalCompliance2 records
Labsystems Diagnostics Oy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Labsystems Diagnostics Oy leadership team
Management profileNumber of profiles
Profiles3 records
Labsystems Diagnostics Oy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Labsystems Diagnostics Oy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Labsystems Diagnostics Oy
What does Labsystems Diagnostics Oy do?
Labsystems Diagnostics Oy develops, manufactures, and markets in-vitro diagnostic products centered on newborn screening, with a complementary portfolio in infectious disease, gastroenterology, clinical biochemistry, point-of-care testing, and life sciences. The company sells reagent kits (tandem MS-based NeoMass AAAC for 50+ inborn metabolic disorders, CAH second tier, SCID-SMA multiplex PCR, FEIA kits), automated instruments (NS2400 high-throughput robotic platform, NS496 Plus DBS Puncher), and consumables to clinical laboratories, hospitals, and screening programs in 70+ countries.
Is Labsystems Diagnostics Oy a public or private company?
Labsystems Diagnostics Oy is a private company. It is classified as corporate owned and is currently operating.
When was Labsystems Diagnostics Oy founded?
Labsystems Diagnostics Oy was founded in 1984. It employs 101 to 250 people.
Where is Labsystems Diagnostics Oy based?
Labsystems Diagnostics Oy is headquartered in Vantaa, Finland, in the Europe region.
How does Labsystems Diagnostics Oy make money?
Three revenue lines are on record. Diagnostic Products Sales are the primary driver. The others are reagent Kits and instrumentation.
Does Labsystems Diagnostics Oy have an API?
No public API is recorded for Labsystems Diagnostics Oy.
What industry is Labsystems Diagnostics Oy in?
Labsystems Diagnostics Oy's product category is In-Vitro Diagnostics / Newborn Screening. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.